The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 2 study exploring the efficacy and safety of 马来酸Pyrotinib
Maleate Tablets in patients with solid tumors with activating（harmful） HER2 mutations or with
HER2 gene amplification or immunohistochemical staining (IHC) assay showing HER2 is 3+ and /
or fluorescence in situ hybridization (FISH) positive.